Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1559-0100
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question ; volume:78 ; number:3 ; day:20 ; month:8 ; year:2022 ; pages:441-445 ; date:12.2022
Endocrine ; 78, Heft 3 (20.8.2022), 441-445, 12.2022
- Urheber
-
Caramella, Irene
Dalla Volta, Alberto
Bergamini, Marco
Cosentini, Deborah
Valcamonico, Francesca
Berruti, Alfredo
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12020-022-03166-w
- URN
-
urn:nbn:de:101:1-2023012021145216846138
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Caramella, Irene
- Dalla Volta, Alberto
- Bergamini, Marco
- Cosentini, Deborah
- Valcamonico, Francesca
- Berruti, Alfredo
- SpringerLink (Online service)
Ähnliche Objekte (12)
Analysis of regulation of angiogenesis by androgen receptor ligands in castration-resistant prostate cancer
Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer
Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription
Clinical characteristics of patients with metastatic castration-resistant prostate cancer after treatment with combined androgen blockade
Patient-derived castration-resistant prostate cancer model revealed CTBP2 upregulation mediated by OCT1 and androgen receptor
Prognostic value of testosterone for the castration-resistant prostate cancer patients: a systematic review and meta-analysis
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Targeting molecular resistance in castration-resistant prostate cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial
The natural compound atraric acid suppresses androgen-regulated neo-angiogenesis of castration-resistant prostate cancer through angiopoietin 2
Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy
Analysis of regulation of angiogenesis by androgen receptor ligands in castration-resistant prostate cancer
Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer
Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription
Clinical characteristics of patients with metastatic castration-resistant prostate cancer after treatment with combined androgen blockade
Patient-derived castration-resistant prostate cancer model revealed CTBP2 upregulation mediated by OCT1 and androgen receptor
Prognostic value of testosterone for the castration-resistant prostate cancer patients: a systematic review and meta-analysis
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Targeting molecular resistance in castration-resistant prostate cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial
The natural compound atraric acid suppresses androgen-regulated neo-angiogenesis of castration-resistant prostate cancer through angiopoietin 2
Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy
Analysis of regulation of angiogenesis by androgen receptor ligands in castration-resistant prostate cancer
Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer
Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription
Clinical characteristics of patients with metastatic castration-resistant prostate cancer after treatment with combined androgen blockade
Patient-derived castration-resistant prostate cancer model revealed CTBP2 upregulation mediated by OCT1 and androgen receptor
Prognostic value of testosterone for the castration-resistant prostate cancer patients: a systematic review and meta-analysis
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Targeting molecular resistance in castration-resistant prostate cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial
The natural compound atraric acid suppresses androgen-regulated neo-angiogenesis of castration-resistant prostate cancer through angiopoietin 2